ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business